Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 3.4%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s share price shot up 3.4% during trading on Tuesday . The stock traded as high as $30.42 and last traded at $30.32. 97,867 shares changed hands during trading, a decline of 78% from the average session volume of 448,974 shares. The stock had previously closed at $29.31.

Analysts Set New Price Targets

Several research firms recently commented on ARCT. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Finally, Citigroup boosted their target price on Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $61.33.

Arcturus Therapeutics Stock Down 8.3 %

The business has a fifty day moving average price of $35.61 and a 200-day moving average price of $29.77.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The firm had revenue of $33.99 million during the quarter, compared to analysts’ expectations of $64.14 million. As a group, research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Transactions at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total value of $610,573.70. Following the completion of the sale, the chief operating officer now owns 473,448 shares of the company’s stock, valued at approximately $16,580,148.96. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. MetLife Investment Management LLC raised its position in Arcturus Therapeutics by 66.3% during the 1st quarter. MetLife Investment Management LLC now owns 12,327 shares of the biotechnology company’s stock valued at $332,000 after purchasing an additional 4,915 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Arcturus Therapeutics by 190.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 217,572 shares of the biotechnology company’s stock valued at $5,866,000 after purchasing an additional 142,633 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Arcturus Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 1,153,513 shares of the biotechnology company’s stock worth $31,099,000 after acquiring an additional 6,291 shares during the period. Federated Hermes Inc. grew its holdings in shares of Arcturus Therapeutics by 1.8% during the 1st quarter. Federated Hermes Inc. now owns 3,761,900 shares of the biotechnology company’s stock worth $101,421,000 after acquiring an additional 66,971 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Arcturus Therapeutics by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 154,551 shares of the biotechnology company’s stock worth $4,167,000 after acquiring an additional 3,704 shares during the period. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.